Integrated Biopharma, Inc.
INBP
$0.3069
$0.01194.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.18% | -0.47% | -0.70% | -0.75% | -5.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.18% | -0.47% | -0.70% | -0.75% | -5.54% |
| Cost of Revenue | -0.25% | -1.62% | -0.38% | 1.09% | -1.80% |
| Gross Profit | 51.64% | 13.53% | -4.36% | -19.79% | -38.55% |
| SG&A Expenses | -2.79% | -6.01% | -7.82% | -8.37% | -7.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.44% | -1.95% | -0.96% | 0.34% | -2.22% |
| Operating Income | 478.33% | 2,108.33% | 109.17% | -115.03% | -126.84% |
| Income Before Tax | 494.31% | 2,052.63% | 168.00% | -114.86% | -127.58% |
| Income Tax Expenses | 3,193.75% | 304.17% | 16.42% | 105.32% | 101.85% |
| Earnings from Continuing Operations | 341.04% | 841.38% | 429.41% | -108.17% | -117.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 341.04% | 841.38% | 429.41% | -108.17% | -117.49% |
| EBIT | 478.33% | 2,108.33% | 109.17% | -115.03% | -126.84% |
| EBITDA | 3,175.86% | 199.20% | 21.02% | -70.78% | -103.26% |
| EPS Basic | 338.76% | 815.00% | 408.33% | -108.21% | -117.50% |
| Normalized Basic EPS | 505.26% | 2,037.50% | 154.55% | -114.94% | -127.24% |
| EPS Diluted | 337.98% | 815.00% | 408.33% | -108.21% | -117.50% |
| Normalized Diluted EPS | 492.21% | 2,271.43% | 152.38% | -117.50% | -129.84% |
| Average Basic Shares Outstanding | 0.42% | 0.49% | 0.39% | 0.31% | 0.29% |
| Average Diluted Shares Outstanding | 0.42% | -0.43% | -0.98% | -0.98% | -1.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
